SavedAdd your journal

Journals / Turkish Journal of Hematology / 2018 / Cilt: 35 - Sayı: 2

Kronik Lenfositik Lösemi ve Mantle Hücreli Lenfoma Ayırıcı Tanısında CD200 ve CD43 Ekspresyonunun Rolü

The Role of CD200 and CD43 Expression in Differential Diagnosis between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Mesude FALAY
Berna AFACAN ÖZTÜRK
Kürşad GÜNEŞ
Yasin KALPAKÇI
Simten DAĞDAŞ
Funda CERAN
Gülsüm ÖZET
Pages
94–98
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CD43 ve CD200 Matutes skorlama sistemi skorunun yetersiz kaldığı KLL olgularının tanısında tamamlayıcı marker olarak kullanılabilir.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Amaç: İmmünfenotip olarak atipik kronik lenfositik lösemi (KLL) ile mantle cell lenfoma (MCL) sıklıkla karışabilmektedir.
📊
Key Findings & Data:Bu çalışmada KLL ve MCL ayırıcı tanısında CD43 ve CD200 ifadeleri araştırılmıştır.
💡
Conclusion & Impact:CD43 ve CD200 Matutes skorlama sistemi skorunun yetersiz kaldığı KLL olgularının tanısında tamamlayıcı marker olarak kullanılabilir.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Amaç: İmmünfenotip olarak atipik kronik lenfositik lösemi (KLL) ile mantle cell lenfoma (MCL) sıklıkla karışabilmektedir. KLL tanısı için birçok marker kullanılmaktadır, ancak akım sitometride KLL tanısı için tam bir konsensüs oluşmamıştır. Bu çalışmada KLL ve MCL ayırıcı tanısında CD43 ve CD200 ifadeleri araştırılmıştır. Gereç ve Yöntemler: Matutes skorlama sisteminde olmayan CD43 ve CD200’ü akım sitometri lenfoproliferatif hastalık paneline dahil ederek 339 KLL ve MCL olgusunda incelenmiştir. Bulgular: Atipik KLL olgularının %97,3’ünde CD200 pozitifken MCL olgularının ise sadece %6,1’inde düşük oranda ifade ediliyordu. CD43’te atipik KLL olgularının %95,7’sinde ifade edilirken MCL olgularının %39,4’ünde donuk ifade ediliyordu. Sonuç: CD43 ve CD200; CD22, CD79b ve FMC7’ye göre daha anlamlı bulundu. CD43 ve CD200 Matutes skorlama sistemi skorunun yetersiz kaldığı KLL olgularının tanısında tamamlayıcı marker olarak kullanılabilir.

Özet

Objective: Atypical chronic lymphocytic leukemia (CLL) is most frequently confused with mantle cell lymphoma (MCL). Several markers may contribute to the diagnosis of CLL. However, there is no consensus on which markers are needed to be used in flow cytometry for the diagnosis of CLL. The aim of the present study was to investigate the role of CD43 and CD200 markers in the differential diagnosis between CLL and MCL.Materials and Methods: To address this issue, 339 consecutive patients with CLL and MCL were included in the flow cytometry lymphoproliferative disease panel for evaluation of CD43 and CD200 expressions, but not in the Matutes scoring system.Results: CD200 was expressed in 97.3% of atypical CLL cases, whereas it was dimly expressed in only 6.1% of MCL cases. CD43 expression was 95.7% in atypical CLL cases. In the MCL cases, its expression rate was 39.4%.Conclusion: CD43 and CD200 were found to be more valuable markers than CD22, CD79b, and FMC7. CD43 and CD200 could also be considered as definitive markers in atypical CLL patients, for whom the Matutes scoring system remains ineffective.

🔖

Cite This Article

FALAY, M., ÖZTÜRK, B. A., GÜNEŞ, K., KALPAKÇI, Y., DAĞDAŞ, S., CERAN, F., ÖZET, G. (2018). Kronik Lenfositik Lösemi ve Mantle Hücreli Lenfoma Ayırıcı Tanısında CD200 ve CD43 Ekspresyonunun Rolü. Turkish Journal of Hematology, Cilt: 35 - Sayı: 2, 94–98. https://ajindex.com/articles/412377

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Jung G, Eisenmann JC, Thiébault S, Hénon P. Cell surface CD43 determination improves diagnostic precision in late B-cell diseases. Br J Haematol 2003
  2. Deneys V, Michaux L, Leveugle P, Mazzon AM, Gillis E, Ferrant A, Scheiff JM, De Bruyère M. Atypical lymphocytic leukemia and mantle cell lymphoma immunologically very close: flow cytometric distinction by the use of CD20 and CD54 expression. Leukemia 2001
  3. Durrieu F, Geneviève F, Arnoulet C, Brumpt C, Capiod JC, Degenne M, Feuillard J, Garand R, Kara-Terki A, Kulhein E, Maynadié M, Ochoa-Noguera ME, Plesa A, Roussel M, Eghbali H, Truchan-Graczyk M, de Carvalho Bittencourt M, Feugier P, Béné MC. Normal levels of peripheral CD19+CD5+ CLL-like cells: toward a defined threshold for CLL follow-up-a GEIL-GOELAMS study. Cytometry B Clin Cytom 2011
  4. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999
  5. Thompson PA, Tam CS. CD38 expression in CLL: a dynamic marker of prognosis. Leuk Lymphoma 2014
  6. Kröber A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P, Döhner H, Stilgenbauer S. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002
  7. Matrai Z. CD38 as a prognostic marker in CLL. Hematology 2005
  8. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, Oscier DG. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002
  9. Angelopoulou MK, Kontopidou FN, Pangalis GA. Adhesion molecules in B-chronic lymphoproliferative disorders. Semin Hematol 1999
  10. Kraus TS, Sillings CN, Saxe DF, Li S, Jaye DL. The role of CD11c expression in the diagnosis of mantle cell lymphoma. Am J Clin Pathol 2010
  11. Stewart CC, Stewart SJ. Immunophenotyping. Immunophenotyping. Curr Protoc Cytom 2001
  12. Gong JZ, Lagoo AS, Peters D, Horvatinovich J, Benz P, Buckley PJ. Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lym